Baseline characteristics

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer · Source last updated 2016-04-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      2061

   2. group Id

      BG001

      value

      2075

   3. group Id

      BG002

      value

      4136

   units

   Participants

groups

1. description

   2.5 mg by mouth (p.o.) once daily

   id

   BG000

   title

   Letrozole

2. description

   1 mg p.o. once daily

   id

   BG001

   title

   Anastrozole

3. description

   Total of all reporting groups

   id

   BG002

   title

   Total

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            8.48

            value

            63.2

         2. group Id

            BG001

            spread

            8.45

            value

            63.1

         3. group Id

            BG002

            spread

            8.46

            value

            63.2

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   Years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            2061

         2. group Id

            BG001

            value

            2075

         3. group Id

            BG002

            value

            4136

      title

      Female

   param Type

   NUMBER

   title

   Sex/Gender, Customized

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice